Wockhardt News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt from all sources in a single place.

Wockhardt Ltd.

10 Jul 2026

1854.50

2.42%

Company Update

Wockhardt Ltd - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed the Certificate received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent of the Company for the quarter ended 30th June, 2026.

pdf

Wockhardt Ltd.

06 Jul 2026

1854.50

2.42%

Looking beyond generics: Wockhardt is showing the way in antibiotics

Business Standard

Wockhardt's FDA-approved Zaynich marks a breakthrough in India's pharmaceutical innovation, offering a new weapon against antimicrobial resistance

Wockhardt Ltd. is trading above its 200 day SMA of 1475.0

Wockhardt Ltd.

03 Jul 2026

1854.50

2.42%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 30 read with Schedule III (Part A Para A) of SEBI Listing Regulations, please find enclosed herewith newspaper extracts of public notice relating to 27th AGM of the Company, published in Lokmat (marathi) - Chhatrapati Sambhajinagar edition and Business Standard (english) - All India editions on Friday, 3rd July, 2026

pdf

Wockhardt Ltd.

26 Jun 2026

1854.50

2.42%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith newspaper advertisement published today i.e. 26th June, 2026, regarding the opening of special window for re-lodgment of the transfer of shares held in physical form.

pdf

Wockhardt Ltd.

25 Jun 2026

1854.50

2.42%

SAST

Wockhardt Ltd - 532300 - Closure of Trading Window

BSE India

This is to inform that pursuant to Company''s ''Code of Conduct for regulating, monitoring and reporting of trading by designated persons'' (''the Code''), the Trading Window for dealing in the equity shares of the Company will be closed from 1st July, 2026 untill 48 hours after the declaration of unaudited financial results of the Company for the quarter ended 30th June, 2026.

pdf

Wockhardt Ltd.

12 Jun 2026, 12:00AM

1854.50

2.42%

Turnaround? Or execution still under scrutiny

Not Rated: Wockhardt Ltd.

Deven Choksey

Wockhardt has transformed into an innovation-led pharmaceutical company with a strong pipeline of novel antibiotics, highlighted by the USFDA approval of Zaynich.

Wockhardt has gained 38.00% in the last 3 Months

Wockhardt Ltd.

11 Jun 2026

1854.50

2.42%

Earnings Call

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Pursuant to Regulation 30 of the Securities and Exchange Board of India (LODR) Regulations, 2015, as amended and in continuation to our letter bearing reference no. Ref.no. WOCK/SEC/SE/2025-26/015 dated 1st June, 2026, please find enclosed the transcript of the Investor Meeting held on Thursday, 4th June, 2026, for your information and records.

pdf

Wockhardt Ltd.

10 Jun 2026

1854.50

2.42%

Wockhardt targets 50% of revenue from novel drugs within five years

Business Standard

Wockhardt expects novel drugs to contribute over half its revenue within five years as it expands a differentiated antibiotic portfolio built through decades of RD

Promoters pledged 0.78% of shares in last quarter. Total pledge stands at 18.82% of promoter holdings

Beyond Zaynich: Wockhardt bets on WCK 6777 as next blockbuster jab

Business Standard | 10 Jun 2026

Wockhardt Ltd.

04 Jun 2026

1854.50

2.42%

Investor Presentation

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Investor Presentation

BSE India

Pursuant to Regulation 30 of SEBI (LODR), Regulations, 2015, please find enclosed herewith copy of the Investor Presentation to be made at the Investor Meeting scheduled to be held on 4th June, 2026.

pdf

Wockhardt Ltd.

02 Jun 2026

1854.50

2.42%

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What's behind the selloff?

Economic Times

Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its March quarter results. Revenue and profit saw significant year-on-year growth. Biotech operations were a key driver of this improved performance.

Promoters pledged 0.78% of shares in last quarter. Total pledge stands at 18.82% of promoter holdings

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Business Line | 02 Jun 2026 5 more

Is Wockhardt Ltd. worth buying?

464 Votes:

Buy 73.49%

Sell 17.03%

Hold 9.48%

RESEARCH REPORTS

Not Rated SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf